Stay updated with breaking news from Both Kaplan Meier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This study is among the first to report outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in stage 5 chronic kidney disease.
This study is among the first to report outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in stage 5 chronic kidney disease (CKD).
This study is among the first to report outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in stage 5 chronic kidney disease.
This study is among the first to report outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in stage 5 chronic kidney disease (CKD).